Jianwei Zhang1, Lingjie He2. 1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University; Beijing-China. 2. Department of Outpatient, Beijing Friendship Hospital, Capital Medical University; Beijing-China.
Abstract
OBJECTIVE: This study aims to investigate the association of circulating miR-660-5p with no-reflow phenomenon (NRP) in patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). METHODS: Consecutive patients diagnosed with anterior STEMI within 12 h of pain onset were included; in these patients, coronary angiography confirmed that the left anterior descending artery was infarcted. Angiographic NRP was defined as a final thrombolysis in myocardial infarction (TIMI) flow 2 or 3 with a myocardial blush grade (MBG) <2. High miR-660-5p was defined as a value in the third tertile. The relationship of circulating miR-660-5p with NRP was assessed using Spearman correlation analysis and multiple logistic regression analysis. RESULTS: Fifty-two eligible patients were finally included in this study (mean age: 56±12.4 years, >65 years: 53.8%, male: 76.9%, and mean Body Mass Index: 26.3±3.5). The incidence of NRP was 38.5%. Circulating miR-660-5p was significantly related to the mean platelet volume (MPV). The patients were grouped into tertiles by miR-660-5p levels (Q1: <7.18, Q2: 7.18-11.31, Q3: >11.31). Those in the high microRNA-660-5p group had nearly a 6-fold higher risk of NRP than those in the low microRNA-660-5p group [odds ratio (OR) = 5.68, 95% confidence interval (CI) 1.40-23.07, p=0.015]. When analyzed by tertiles, relative odds of NRP were consistently increasing (OR1 for Q2 vs. Q1: 1.25, 95% CI: 0.27-5.73, p=0.770; OR2 for Q3 vs. Q1: 5.96, 95% CI: 1.33-26.66, p=0.02), despite multivariable adjustment. Receiver operating characteristic curve analysis demonstrated that the microRNA-660-5p level of 10.17 was the best cut-off level to predict the incidence of the NRP in patients undergoing PPCI with an area under the ROC curve (AUC) of 0.768 (95% CI: 0.636-0.890). CONCLUSION: Circulating miR-660-5p was significantly associated with NRP, and it may be a useful biomarker to predict the incidence of NRP in patients with STEMI undergoing PPCI.
OBJECTIVE: This study aims to investigate the association of circulating miR-660-5p with no-reflow phenomenon (NRP) in patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). METHODS: Consecutive patients diagnosed with anterior STEMI within 12 h of pain onset were included; in these patients, coronary angiography confirmed that the left anterior descending artery was infarcted. Angiographic NRP was defined as a final thrombolysis in myocardial infarction (TIMI) flow 2 or 3 with a myocardial blush grade (MBG) <2. High miR-660-5p was defined as a value in the third tertile. The relationship of circulating miR-660-5p with NRP was assessed using Spearman correlation analysis and multiple logistic regression analysis. RESULTS: Fifty-two eligible patients were finally included in this study (mean age: 56±12.4 years, >65 years: 53.8%, male: 76.9%, and mean Body Mass Index: 26.3±3.5). The incidence of NRP was 38.5%. Circulating miR-660-5p was significantly related to the mean platelet volume (MPV). The patients were grouped into tertiles by miR-660-5p levels (Q1: <7.18, Q2: 7.18-11.31, Q3: >11.31). Those in the high microRNA-660-5p group had nearly a 6-fold higher risk of NRP than those in the low microRNA-660-5p group [odds ratio (OR) = 5.68, 95% confidence interval (CI) 1.40-23.07, p=0.015]. When analyzed by tertiles, relative odds of NRP were consistently increasing (OR1 for Q2 vs. Q1: 1.25, 95% CI: 0.27-5.73, p=0.770; OR2 for Q3 vs. Q1: 5.96, 95% CI: 1.33-26.66, p=0.02), despite multivariable adjustment. Receiver operating characteristic curve analysis demonstrated that the microRNA-660-5p level of 10.17 was the best cut-off level to predict the incidence of the NRP in patients undergoing PPCI with an area under the ROC curve (AUC) of 0.768 (95% CI: 0.636-0.890). CONCLUSION: Circulating miR-660-5p was significantly associated with NRP, and it may be a useful biomarker to predict the incidence of NRP in patients with STEMI undergoing PPCI.
Authors: Giampaolo Niccoli; Andrea Celestini; Camilla Calvieri; Nicola Cosentino; Elena Falcioni; Roberto Carnevale; Cristina Nocella; Francesco Fracassi; Marco Roberto; Roberta P Antonazzo; Pasquale Pignatelli; Filippo Crea; Francesco Violi Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-09-05
Authors: Bianca Rocca; Paola Secchiero; Giovanni Ciabattoni; Franco O Ranelletti; Lucia Catani; Lia Guidotti; Elisabetta Melloni; Nicola Maggiano; Giorgio Zauli; Carlo Patrono Journal: Proc Natl Acad Sci U S A Date: 2002-05-28 Impact factor: 11.205
Authors: Jing Li; Xi Li; Qing Wang; Shuang Hu; Yongfei Wang; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang Journal: Lancet Date: 2014-06-23 Impact factor: 79.321
Authors: Frederic S Resnic; Marco Wainstein; Michael K Y Lee; Dominik Behrendt; Rodrigo V Wainstein; Lucila Ohno-Machado; James M Kirshenbaum; Campbell D K Rogers; Jeffrey J Popma; Robert Piana Journal: Am Heart J Date: 2003-01 Impact factor: 4.749
Authors: C Michael Gibson; Sabina A Murphy; David A Morrow; Julian M Aroesty; Raymond J Gibbons; Steven G Gourlay; Hal V Barron; Robert P Giugliano; Elliott M Antman; Eugene Braunwald Journal: Am Heart J Date: 2004-08 Impact factor: 4.749
Authors: Zenon Huczek; Krzysztof J Filipiak; Janusz Kochman; Radoslaw Piatkowski; Marcin Grabowski; Marek Roik; Lukasz A Malek; Pawel Jaworski; Grzegorz Opolski Journal: Am Heart J Date: 2007-07 Impact factor: 4.749
Authors: Philipp Jakob; Tim Kacprowski; Sylvie Briand-Schumacher; Dik Heg; Roland Klingenberg; Barbara E Stähli; Milosz Jaguszewski; Nicolas Rodondi; David Nanchen; Lorenz Räber; Pierre Vogt; Francois Mach; Stephan Windecker; Uwe Völker; Christian M Matter; Thomas F Lüscher; Ulf Landmesser Journal: Eur Heart J Date: 2017-02-14 Impact factor: 29.983